Teprotumumab
Approved · EMAAlso known as Tepezza.
Recent clinical, regulatory, research and industry developments relating to this drug.
Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza
Under-the-skin Tepezza comparable to infused version in key study, Amgen says
Amgen seeks to buoy Tepezza with injectable data in face of incoming competition
Amgen scores with trial of on-body injected version of Tepezza in thyroid eye disease
Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Teprotumumab for Thyroid-Associated Ophthalmopathy.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Treatment of moderate to severe thyroid eye disease (TED).
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- The New England journal of medicine2
- Antonelli A2
- Douglas RS2
- Fleming JC2
- Harris GJ2
- Kahaly GJ2
- Salvi M2
- Smith TJ2
- Couch SM1
- From Cedars-Sinai Medical Center1
- Kellogg Eye Center (T.J.S.1
- RxNorm (U.S. National Library of Medicine) — drug identity
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.